Transgene and Randox Sign Collaboration to Develop Innovative Multifunctional Oncolytic Virotherapies for Solid Tumors

Novel Oncolytic Virotherapies will be developed by Transgene, based on its next generation Invir.IOTM Platform and expressing Randox’ Single-domain Antibodies (SdAb)   Strasbourg (France) and Belfast (Northern Ireland), October 2, 2017, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops viral-based immunotherapies, and Randox, a global leader in in vitro … Continued

Read More

10th Annual European Life Science CEO Forum & Exhibition (ELSCEO)

Head of Biomarker Services at Randox Biosciences, Dr Claire Huguet, will be travelling to Switzerland this coming March to attend the 10th Annual ELSCEO Forum & Exhibition. This event will be highly transactional, bringing together an exciting cross-section of venture-funded and small-cap companies with leading investors, pharmas, and scientific thought leaders, as well as over  350 … Continued

Read More